CVRx(CVRX)

Search documents
CVRx(CVRX) - 2024 Q1 - Earnings Call Transcript
2024-05-01 02:38
CVRx, Inc. (NASDAQ:CVRX) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Mike Vallie - IR Kevin Hykes - President and CEO Jared Oasheim - CFO Conference Call Participants Lilia-Celine Lozada - JPMorgan Phillip Dantoin - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Operator Greetings, and welcome to the CVRx Q1 2024 Earnings Call. [Operator Instructions] As a reminder, th ...
CVRx(CVRX) - 2024 Q1 - Quarterly Results
2024-04-30 20:15
Exhibit 99.1 CVRx Reports First Quarter 2024 Financial and Operating Results MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights "We had a solid first quarter, which was offset by some commercial exec ...
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
Zacks Investment Research· 2024-04-19 16:16
CVRx, Inc. (CVRX) recently announced the availability of additional data supporting the long-term benefits of Barostim. This includes the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight the long-term sustained benefits of Barostim in heart failure (HF) patients with reduced ejection fraction.It should be noted that BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April 2016 to develop scient ...
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
Newsfilter· 2024-04-16 20:30
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm ...
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
GlobeNewsWire· 2024-04-16 20:30
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm ...
CVRx announces availability of additional data supporting long-term benefits of Barostim
Newsfilter· 2024-04-15 11:30
BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits of Barostim in heart failure patien ...
CVRx(CVRX) - 2023 Q4 - Annual Report
2024-02-08 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40545 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1983744 (State or other jurisdiction o ...
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
Newsfilter· 2024-01-31 13:00
Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will ...
New Strong Buy Stocks for January 30th
Zacks Investment Research· 2024-01-30 12:21
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Warrior Met Coal, Inc. (HCC) : This metallurgical coal mining company has seen the Zacks Consensus Estimate for its current year earnings increasing 9.9% over the last 60 days.Eldorado Gold Corporation (EGO) : This mining and exploration company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.5% over the last 60 days.World Acceptance Corporation (WRLD) : This consumer finance company has seen the Zacks ...
CVRx(CVRX) - 2023 Q4 - Earnings Call Transcript
2024-01-26 03:37
CVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Conference Call January 25, 2024 4:30 PM ET Company Participants Mike Vallie - IR Nadim Yared - President and CEO Jared Oasheim - CFO Conference Call Participants Margaret Andrew - William Blair Matthew O'Brien - Piper Sandler Robbie Marcus - JPMorgan Bill Plovanic - Canaccord Alex Nowak - Craig-Hallum Frank Takkinen - Lake Street Operator Greetings, and welcome to the CVRx Fourth Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is ...